NCT04746430.

Methods	Trial design: open‐label RCT Sample size: 2000 Setting: outpatient Language: Dutch, English Number of centres: no information Type of intervention (treatment/prevention): treatment
Participants	Inclusion criteria Age ≥ 18 years A positive test for SARS‐CoV‐2 GP consultation for deteriorating COVID‐19 symptoms Additional inclusion criteria in order to be eligible for randomisation to the trial: Exercise‐induced desaturation, defined as SpO2 < 92% (< 90% for COPD patients) and/or an absolute drop of ≥ 4% in SpO2 after a 1‐min sit‐to‐stand test OR SpO2 < 92% (< 90% for COPD patients) at rest with GP's and patient's shared decision to keep patient at home despite this in itself being an indication for referral to hospital Exclusion criteria Inability to understand and sign the written consent form Inability to perform saturation measurements or sit‐to‐stand test Not willing to be admitted to hospital On the discretion of the recruiting clinician if he or she deems a patient not eligible Contra‐indication for dexamethasone
Interventions	Details of intervention: Dose: 6 mg dexamethasone prescribed for 10 days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms Route of administration: most likely systemic Treatment details of control group (e.g. dose, route of administration): only remote monitoring Concomitant therapy: no information
Outcomes	Primary outcome: time to first hospital admission or death (time frame: 28 days)
Notes	Recruitment status: terminated (too few patients) Prospective completion date: March 2022 Date last update was posted: 5 April 2021 Sponsor/funding: General Practitioners Research Institute